ATH434 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 17 | 多系統萎縮症 | 2 |
17. 多系統萎縮症
臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05732415 (ClinicalTrials.gov) | March 1, 2023 | 8/2/2023 | Biomarker Study of ATH434 in Participants With MSA | An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy | Multiple System Atrophy | Drug: ATH434 | Alterity Therapeutics | NULL | Not yet recruiting | 30 Years | 75 Years | All | 15 | Phase 2 | United States |
| 2 | NCT05109091 (ClinicalTrials.gov) | July 1, 2022 | 22/10/2021 | Study of ATH434 in Participants With Multiple System Atrophy | A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy | Multiple System Atrophy | Drug: ATH434 dose level 1;Drug: ATH434 dose level 2;Drug: Placebo | Alterity Therapeutics | NULL | Recruiting | 30 Years | 75 Years | All | 60 | Phase 2 | United States;Australia;Italy;New Zealand;United Kingdom |